Safety of IL17/23 Inhibitors in Patients with Psoriasis or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
Published: 2 June 2020| Version 1 | DOI: 10.17632/pff4wtbwcd.1
Contributor:
yuwen suDescription
Supplemental figures and tables for 'Safety of IL17/23 Inhibitors in Patients with Psoriasis or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis'.
Files
Categories
Incidence Group